SYGNIS announces the adaptation of its organisation to the new business activity

03-Jan-2013 - Germany

SYGNIS Pharma announced the discontinuation of its therapeutic R&D project KIBRA and the adaptation of its organisation to the new business activity. At the Heidelberg site the staff will be reduced by 10 employees.

These measures are implemented to concentrate the financial resources on the development and marketing of novel technologies in molecular biology in line with the new corporate strategy. This new business was acquired in 2012 by joining forces with the Spanish X-Pol Biotech.

Other news from the department business & finance

Most read news

More news from our other portals

Last viewed contents

Images of NMDA receptors help explain how they are affected by zinc and a drug

Images of NMDA receptors help explain how they are affected by zinc and a drug

Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies - Ikarovec is developing novel gene therapies to treat serious, but common eye diseases

Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies - Ikarovec is developing novel gene therapies to treat serious, but common eye diseases

The Linde Group and Algenol Biofuels agree to cooperate in CO2 and O2 management for biofuel production from algae

RNA Healer receives around one million euros for the development of a liver fibrosis therapy - MHH project wins start-up funding competition organised by Lower Saxony research incubator Institute for Biomedical Translation Lower Saxony.

RNA Healer receives around one million euros for the development of a liver fibrosis therapy - MHH project wins start-up funding competition organised by Lower Saxony research incubator Institute for Biomedical Translation Lower Saxony.

Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders - Launch of Start-up QLi5 Therapeutics

Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders - Launch of Start-up QLi5 Therapeutics

Biomass for biofuels, biochemicals will more than triple to 3.7 billion tons in 2030

Thianthrenium chemistry allows for reactivity switch of a nucleophilic amino acid into a versatile intermediate - Useful and broadly applicable tool in the field of chemical biology

Thianthrenium chemistry allows for reactivity switch of a nucleophilic amino acid into a versatile intermediate - Useful and broadly applicable tool in the field of chemical biology

U.S. Department Of Defense selects Applied Biosystems for development of instrument system to identify infectious diseases

NLS Pharma acquires a portfolio of strategic patents - Critical step in the novel development of a potential non-amphetaminic stimulant for ADHD

Boehringer Ingelheim announces change in the company management - Harsha Deshmukh has been appointed as a member of the Executive Board with responsibility for IT and Global Business Services with effect from February 1, 2026

Boehringer Ingelheim announces change in the company management - Harsha Deshmukh has been appointed as a member of the Executive Board with responsibility for IT and Global Business Services with effect from February 1, 2026

Midatech and Immunotope Form Joint Venture, Syntara LLC, for the Development of Immune Therapies

Singapore Launches Infrastructure for Metrology in Chemistry (MiC)